Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and whose condition has reached a point where treatment is needed, based on international medical guidelines from 2018.
• People for whom a doctor has already decided — before and separately from this study — to start a specific combination treatment using two medicines called ibrutinib and venetoclax, used together for a set period of time.
• People who are willing to sign a consent form that allows the trial site to verify their medical records, in line with local rules.
• People who are able to read, understand, and fill in questionnaires about their health and wellbeing in their local language throughout the study.

Who may not be able to join:

• People who have previously received any treatment for CLL or SLL.
• People who have taken part in a trial involving an experimental medicine, vaccine, or invasive experimental medical device within the 30 days before the study begins or before the first data collection point.
• People who are currently enrolled in, or plan to join, another clinical trial that involves an active medical intervention (participation in observational studies or registries not run by Janssen may be permitted — confirm with trial site).
• People for whom there are any restrictions or limitations under the currently approved prescribing guidelines for ibrutinib or venetoclax in Romania that would prevent treatment with this combination.

Important: Always verify eligibility with the trial site directly before applying.